Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2024-03-14 Capital/Financing Update
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Amended Appendix 3B 3 pages 229.0KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Amended Appendix 3B' and relates to amendments concerning the settlement and issue dates of new shares under an Institutional Entitlement Offer. It includes a detailed timetable for the equity raising process and references an earlier ASX announcement about the equity raising. The content focuses on capital raising activities, share issuance, and trading commencement dates. There is no financial performance data, audit information, or management discussion. The document is an update on financing activities, specifically about share issuance and capital structure changes. Therefore, it fits best under the category 'Capital/Financing Update' (CAP). The document length is about 5370 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2024-03-14 English
Trading Halt 3 pages 304.1KB
Capital/Financing Update Classification · 100% confidence The document is a market announcement from PYC Therapeutics Limited regarding a trading halt requested pending a capital raising announcement. It references Listing Rule 17.1 and states that the trading halt will remain until the announcement is released. The document does not contain financial statements, detailed financial data, or a report itself, but rather is an announcement about a trading halt related to an upcoming capital raising. The document length is short (2629 characters), and it is clearly an announcement rather than a report. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-03-13 English
PYC Equity Raising to Raise up to $74.6 Million 6 pages 301.1KB
Capital/Financing Update Classification · 100% confidence The document is an announcement by PYC Therapeutics Limited regarding a capital raising through an accelerated non-renounceable entitlement offer. It details the offer price, discount, use of funds, timetable, and shareholder participation. There are no financial statements or detailed financial performance data included. The document focuses on fundraising activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the capital raising but is not a full financial report or earnings release.
2024-03-13 English
PYC Equity Raising Presentation 41 pages 1.7MB
Capital/Financing Update Classification · 95% confidence The document is a detailed presentation by PYC Therapeutics Limited regarding a $75 million capital raising through a pro-rata accelerated non-renounceable entitlement offer. It includes disclaimers, investment risks, corporate structure, capital structure pre-raise, shareholder information, and details about the equity raise structure. The content focuses on fundraising activities, capital structure, and investor information related to the equity raising. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. The document is clearly a presentation aimed at investors about the capital raising and related strategic information. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2024-03-13 English
Proposed issue of securities - PYC 6 pages 21.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from PYC Therapeutics Limited regarding a proposed accelerated entitlement offer of ordinary fully paid shares. It details the number of securities to be issued, offer prices, timetable, and purpose of the capital raised. The content focuses on fundraising and capital structure changes, including offer conditions, pricing, and dates. There are no financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result announcement. The document fits the description of a Capital/Financing Update, as it provides updates on company fundraising and capital structure changes.
2024-03-13 English
Cleansing Notice Under Section 708AA 4 pages 324.4KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) regarding a pro-rata accelerated non-renounceable entitlement offer by PYC Therapeutics Limited. It details the structure, potential effects on control, major shareholder participation, and voting power implications of the entitlement offer. The document is an announcement about a capital raising event and the issuance of new shares, including legal and regulatory compliance statements. There are no financial statements or detailed financial performance data presented. The content focuses on the capital raising activity and shareholder implications, which aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-03-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.